scholarly journals Impact of Conditioning Intensity with or without Total Body Irradiation on Acute Graft-Versus-Host Disease and Clinical Outcomes

2014 ◽  
Vol 20 (2) ◽  
pp. S275-S276
Author(s):  
Hideki Nakasone ◽  
Takahiro Fukuda ◽  
Junya Kanda ◽  
Takehiko Mori ◽  
Takanori Teshima ◽  
...  
Keyword(s):  
Clinical Outcomes ◽  
Graft Versus Host Disease ◽  
Total Body Irradiation ◽  
Host Disease ◽  
Graft Versus Host ◽  
Total Body ◽  
Conditioning Intensity ◽  
Acute Graft

The Effect of the Order of Total Body Irradiation and Chemotherapy on Graft-Versus-Host Disease

2014 ◽  
Vol 36 (1) ◽  
pp. e9-e12 ◽  
Author(s):  
Motohiro Kato ◽  
Ryosuke Shiozawa ◽  
Katsuyoshi Koh ◽  
Yoshihisa Nagatoshi ◽  
Junko Takita ◽  
...  
Keyword(s):  
Graft Versus Host Disease ◽  
Total Body Irradiation ◽  
Host Disease ◽  
Graft Versus Host ◽  
Total Body

Increased Risk of Chronic Graft-Versus-Host Disease, Obstructive Bronchiolitis, and Alopecia With Busulfan Versus Total Body Irradiation: Long-Term Results of a Randomized Trial in Allogeneic Marrow Recipients With Leukemia

Blood ◽  
1999 ◽  
Vol 93 (7) ◽  
pp. 2196-2201 ◽  
Author(s):  
O. Ringdén ◽  
M. Remberger ◽  
T. Ruutu ◽  
J. Nikoskelainen ◽  
L. Volin ◽  
...  
Keyword(s):  
Graft Versus Host Disease ◽  
Total Body Irradiation ◽  
Advanced Disease ◽  
Group Versus ◽  
Long Term Results ◽  
Early Disease ◽  
Host Disease ◽  
Graft Versus Host ◽  
Increased Risk ◽  
Total Body

Abstract Leukemic patients receiving marrow from HLA-identical sibling donors were randomized to treatment with either busulfan 16 mg/kg (n = 88) or total body irradiation ([TBI] n = 79) in addition to cyclophosphamide 120 mg/kg. The patients were observed for a period of 5 to 9 years. Busulfan-treated patients had an increased risk of veno-occlusive disease (VOD) of the liver (12% v 1%,P = .01) and hemorrhagic cystitis (32% v 10%,P = .003). Acute graft-versus-host disease (GVHD) was similar in the two groups, but the 7-year cumulative incidence of chronic GVHD was 59% in the busulfan-treated group versus 47% in the TBI group (P = .05). Death from GVHD was more common in the busulfan group (22% v 3%, P < .001). Obstructive bronchiolitis occurred in 26% of the busulfan patients but in only 5% of the TBI patients (P < .01). Complete alopecia developed in 8 busulfan patients and partial alopecia in 17, versus five with partial alopecia in the TBI group (P < .001). Cataracts occurred in 5 busulfan-treated patients and 16 TBI patients (P = .02). The incidence of relapse after 7 years was 29% in both groups. Seven-year transplant-related mortality (TRM) in patients with early disease was 21% in the busulfan group and 12% in the TBI group. In patients with more advanced disease, the corresponding figures were 64% and 22%, respectively (P = .004). Leukemia-free survival (LFS) in patients with early disease was 68% in busulfan-treated patients and 66% in TBI patients. However, 7-year LFS in patients with more advanced disease was 17% in the busulfan group versus 49% in the TBI group (P < .01). In patients with chronic myeloid leukemia (CML) in first chronic phase, 7-year LFS was 72% and 83% in the two groups, respectively.

Sign in / Sign up

Export Citation Format

Share Document